Mablink

Lyon, France Founded: 2018 • Age: 8 yrs Acquired By Lilly
Antibody-drug conjugate technology for cancer treatment is provided.

About Mablink

Mablink is a company based in Lyon (France) founded in 2018 by Charles Dumontet, Warren Viricel, Benoit Joseph, and Jean Guillaume Lafay was acquired by Lilly in October 2023.. Mablink has raised $35 million across 3 funding rounds from investors including Lilly, Crédit Agricole and Elaia. Mablink operates in a competitive market with competitors including BeiGene, Moderna, GSK, Incyte and Avidity Biosciences, among others.

  • Headquarter Lyon, France
  • Founders Charles Dumontet, Warren Viricel, Benoit Joseph, Jean Guillaume Lafay
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Pharmaceuticals & Therapeutics
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $35 M (USD)

    in 3 rounds

  • Latest Funding Round
    $30.17 M (USD), Series A

    Oct 14, 2022

  • Investors
    Lilly

    & 9 more

  • Employee Count
    Employee Count
  • Acquired by
    Lilly

    (Oct 18, 2023)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal
People of Mablink
Headcount 10-50
Employee Profiles 15
Employee Profiles
People
Pierrick Bruyat
Research Scientist in Medicinal Chemistry
People
Stanislas Sordet
Chief Financial Officer
People
Jean-Guillaume Lafay
Chief Executive Officer & Co-Founder
People
Edouard LEROY
Chief Business Officer

Unlock access to complete

Funding Insights of Mablink

Mablink has successfully raised a total of $35M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $30.17 million completed in October 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 3
  • Last Round Series A — $30.2M
  • First Round

    (01 Jun 2018)

  • Investors Count 9
Date Amount Transaction Name Valuation Lead Investors Investors
Oct, 2022 Amount Series A - Mablink Valuation Sofinnova Partners , Merieux Equity Partners
Apr, 2021 Amount Seed - Mablink Valuation Elaia
Jun, 2018 Amount Grant - Mablink Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Mablink

Mablink has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly, Crédit Agricole and Elaia. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Venture capital firm focused on early-stage investments
Founded Year Domain Location
-
Founded Year Domain Location
Cancer research is supported through funding and entrepreneurial guidance.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Mablink

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Mablink

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Mablink Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Mablink

Mablink operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BeiGene, Moderna, GSK, Incyte and Avidity Biosciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Targeted and immune-oncology drugs for cancer treatment are developed.
domain founded_year HQ Location
mRNA-based therapeutics for diseases including cancer and infections are developed.
domain founded_year HQ Location
Developer of pharmaceuticals and vaccines for various therapeutic areas
domain founded_year HQ Location
Small molecules are developed for cancer and skin disease treatments.
domain founded_year HQ Location
Antibody-siRNA complexes are developed for cancer treatment.
domain founded_year HQ Location
ALX Oncology is focused on advancing cancer treatment therapies.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Mablink

Frequently Asked Questions about Mablink

When was Mablink founded?

Mablink was founded in 2018.

Where is Mablink located?

Mablink is headquartered in Lyon, France. It is registered at Lyon, Auvergne-rhone-alpes, France.

Is Mablink a funded company?

Mablink is a funded company, having raised a total of $35M across 3 funding rounds to date. The company's 1st funding round was a Grant of $1.72M, raised on Jun 01, 2018.

What does Mablink do?

Mablink was established in 2018 in Lyon, France, within the biotechnology sector. Antibody-drug conjugates for oncology applications are developed using a proprietary hydrophilic linker platform. This platform incorporates a non-polymeric 2.0 kDa linker that maintains plasma stability in homogeneous ADCs, without reliance on site-specific conjugation. Targeted products include MBK-101 and MBK-102, addressing acute myeloid leukemia and multiple myeloma.

Who are the top competitors of Mablink?

Mablink's top competitors include Moderna, BeiGene and Strand Therapeutics.

Who are Mablink's investors?

Mablink has 10 investors. Key investors include Lilly, Crédit Agricole, Elaia, Pertinence Invest, and Foundation Fournier-Majoie.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available